3 R&D centres

Ipsen has set-up its R&D centres at the heart of three internationally reputed scientific hubs: Paris-Saclay in France, Oxford in the United Kingdom, and Cambridge in the United States. Each site is located close to leading academic research centres, cutting-edge medical centres and biotechnological companies. Interactions with key health industry players greatly increase our chances of access to innovative technologies to speed up the discovery and approval of drugs and services that improve the lives of patients.

 
The Ipsen R&D centre (Ipsen Bioinnovation) in Abingdon , close to Oxford, has been designed to encourage innovation and foster collaboration. It is home to Ipsen’s technological platform for toxins. Beyond experimental science, the new building co-locates the major R&D activities of clinical development, scientific affairs, regulatory affairs, pharmacovigilance, project management and publication.

Ipsen Bioinnovation is a pioneering research and development organization with unique experience in recombinant botulinum toxin technology. Researchers and scientists in the United Kingdom work to expand their understanding of botulinum neurotoxins and discover and develop entirely new molecular compounds that are designed to treat disease and improve quality of life for patients.

The botulinum toxin platform has very broad therapeutic potential in many areas: neuroscience as well as oncology, endocrinology and regenerative medicine.

Ipsen Bioinnovation continues to be a leading innovator and secured more than 200 patents and pending patents. Working together with some of the most prestigious institutions, hospitals and scientists in the world, Ipsen Bioinnovation is committed to establishing partnerships and collaborations that will drive research forward and provide solutions to address unmet medical needs. As part of the Ipsen Group, Ipsen Bioinnovation is able to not only to discover new therapeutic candidates, but also to provide the pharmacological, preclinical and clinical assessment of these newly discovered compounds and eventually bring them to the patients who need them the most.

With our unparalleled toxins capability, Ipsen Bioinnovation is dedicated to building a full toxin portfolio and focused on developing new formulations that will better address patients’ needs and expand the spectrum of clinical applications.

John Chaddock, PhD
VP, Neurology-Site Head

 

> 13%

of sales invested in R&D in 2015

3

global R&D centres

~300

employees assigned to R&D

Date of preparation January 2018 / ALL-UK-000455